The Joint Corp.

NasdaqCM:JYNT Stock Report

Market Cap: US$122.6m

Joint Valuation

Is JYNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of JYNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: JYNT ($8.95) is trading below our estimate of future cash flow value ($44.05)

Significantly Below Future Cash Flow Value: JYNT is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JYNT?

Key metric: As JYNT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JYNT. This is calculated by dividing JYNT's market cap by their current earnings.
What is JYNT's PE Ratio?
PE Ratio91.4x
EarningsUS$1.34m
Market CapUS$122.56m

Price to Earnings Ratio vs Peers

How does JYNT's PE Ratio compare to its peers?

The above table shows the PE ratio for JYNT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.4x
CYH Community Health Systems
0.8x-109.55%US$379.3m
AUNA Auna
15.9x44.02%US$319.0m
USPH U.S. Physical Therapy
123x47.46%US$943.0m
ARDT Ardent Health
9.9x12.93%US$1.3b
JYNT Joint
91.4x75.53%US$122.6m

Price-To-Earnings vs Peers: JYNT is expensive based on its Price-To-Earnings Ratio (91.4x) compared to the peer average (37.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does JYNT's PE Ratio compare vs other companies in the US Healthcare Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.8x-109.55%US$379.27m
IDXG Interpace Biosciences
2.1xn/aUS$50.42m
RHEP Regional Health Properties
1.3xn/aUS$4.99m
MDCE Medical Care Technologies
4.2xn/aUS$975.05k
JYNT 91.4xIndustry Avg. 24.6xNo. of Companies12PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JYNT is expensive based on its Price-To-Earnings Ratio (91.4x) compared to the US Healthcare industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is JYNT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JYNT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio91.4x
Fair PE Ratio48.7x

Price-To-Earnings vs Fair Ratio: JYNT is expensive based on its Price-To-Earnings Ratio (91.4x) compared to the estimated Fair Price-To-Earnings Ratio (48.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JYNT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.95
US$10.00
+11.73%
14.14%US$12.00US$9.00n/a3
May ’27US$8.90
US$10.00
+12.36%
14.14%US$12.00US$9.00n/a3
Apr ’27US$8.58
US$10.00
+16.55%
14.14%US$12.00US$9.00n/a3
Mar ’27US$8.80
US$10.67
+21.21%
22.10%US$14.00US$9.00n/a3
Feb ’27US$9.78
US$10.67
+9.07%
22.10%US$14.00US$9.00n/a3
Jan ’27US$8.72
US$10.67
+22.32%
22.10%US$14.00US$9.00n/a3
Dec ’26US$8.35
US$10.75
+28.74%
19.04%US$14.00US$9.00n/a4
Nov ’26US$7.89
US$14.88
+88.53%
18.47%US$18.00US$10.50n/a4
Oct ’26US$9.27
US$14.88
+60.46%
18.47%US$18.00US$10.50n/a4
Sep ’26US$10.74
US$14.88
+38.50%
18.47%US$18.00US$10.50n/a4
Aug ’26US$10.93
US$15.38
+40.67%
21.98%US$20.00US$10.50n/a4
Jul ’26US$11.56
US$15.38
+33.00%
21.98%US$20.00US$10.50n/a4
Jun ’26US$10.70
US$15.38
+43.69%
21.98%US$20.00US$10.50n/a4
May ’26US$10.34
US$16.38
+58.37%
24.18%US$20.00US$10.50US$8.904
Apr ’26US$12.17
US$16.38
+34.55%
24.18%US$20.00US$10.50US$8.584
Mar ’26US$11.35
US$16.38
+44.27%
24.18%US$20.00US$10.50US$8.804
Feb ’26US$11.05
US$16.38
+48.19%
24.18%US$20.00US$10.50US$9.784
Jan ’26US$10.63
US$16.38
+54.05%
24.18%US$20.00US$10.50US$8.724
Dec ’25US$11.64
US$16.38
+40.68%
24.18%US$20.00US$10.50US$8.354
Nov ’25US$11.08
US$16.63
+50.05%
23.43%US$20.00US$10.50US$7.894
Oct ’25US$11.10
US$16.63
+49.77%
23.43%US$20.00US$10.50US$9.274
Sep ’25US$11.31
US$16.63
+46.99%
23.43%US$20.00US$10.50US$10.744
Aug ’25US$13.26
US$15.38
+15.95%
21.98%US$20.00US$10.50US$10.934
Jul ’25US$13.20
US$15.38
+16.48%
21.98%US$20.00US$10.50US$11.564
Jun ’25US$15.01
US$15.38
+2.43%
21.98%US$20.00US$10.50US$10.704
May ’25US$12.79
US$12.19
-4.71%
18.54%US$15.00US$8.75US$10.344
US$10
Fair Value
10.5% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 11:59
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Joint Corp. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey Van SinderenB. Riley Securities, Inc.
Jeremy HamblinCraig-Hallum Capital Group LLC
Linda Bolton-WeiserD.A. Davidson & Co.